Advexin FDA Approval Status
FDA Approved: No
Brand name: Advexin
Generic name: p53 tumor suppressor therapy
Company: Introgen Therapeutics, Inc.
Treatment for: Head and Neck Cancer
Advexin is an investigational targeted molecular therapy for the treatment of head and neck cancer.
In September 2008, Introgen Therapeutics, Inc. announced the receipt Refuse to File Letter from the U.S. Food and Drug Administration (FDA), advising the company that the Biologics License Application (BLA) for Advexin was not sufficiently complete and would not be filed at that time.
Development timeline for Advexin
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.